Advances in Oncology, 2024

1st Edition, Volume 4-1 - April 1, 2024
Editor: Leonidas C. Platanias
Language: English
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 2 4 7 0 0 - 2
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 2 4 7 0 1 - 9

Advances in Oncology reviews the year’s most important findings and updates within the field in order to provide practicing oncologists with the current clinical information… Read more

Purchase options

Info / Buy

Institutional subscription on ScienceDirect

Request a sales quote

Advances in Oncology reviews the year’s most important findings and updates within the field in order to provide practicing oncologists with the current clinical information they need to improve patient outcomes. A distinguished editorial board, led by Dr. Leonidas C. Platanias, identifies key areas of major progress and controversy and invites preeminent specialists to contribute original articles devoted to these topics. These insightful overviews in oncology inform and enhance clinical practice by bringing concepts to a clinical level and exploring their everyday impact on patient care.

Cover image
Title page
Table of Contents
Copyright
Editorial Board
Contributors
Preface
SECTION I: SURGICAL ONCOLOGY
Contemporary Management of Dermatofibrosarcoma Protuberans
Key points
Introduction
Surgical management of dermatofibrosarcoma protuberans
Management of recurrent or unresectable disease
Surveillance
Future directions
Summary
Clinics care points
Management of Locoregional Melanoma
Key points
Introduction
Section I: management of the primary site
Section II: regional disease management
Section III: management of advanced disease
Summary
Key Clinical Concepts of Locoregional Melanoma Management
Clinics care points
Current Management of Intraductal Papillary Mucinous Neoplasms
Key points
Classification
Surveillance
Surgery
Follow-up
Clinics care points
SECTION II: MEDICAL ONCOLOGY
Perioperative Strategies in Non-Small Cell Lung Cancer: Immunotherapy and Targeted Therapy
Key points
Introduction
Adjuvant therapy
Neoadjuvant therapy
Perioperative therapy
Debates and controversies
Future directions
Summary
Clinics care points
Optimal Front-Line Therapy for Non-Oncogene-Driven Non-Small Cell Lung Cancer
Key points
Introduction
Programmed death-ligand 1 assays
Tumor mutational burden
Approach to advanced non-small cell lung cancer
Treatment for non-oncogene-driven non-small cell lung cancer
General approach to treatment
Duration of treatment
Toxicities
Special considerations
Summary
Clinics care points
Beyond First-Line Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKI): Approach to Resistance
Key points
Background
EGFR-dependent resistance mechanisms
Non-EGFR-dependent resistance mechanisms
Approach A: how to overcome resistance—non-targeted approach at the time of resistance
Approach B: how to overcome resistance—targeted approach at the time of resistance
Approach C: how to overcome resistance—prior to the development of resistance
Summary
SECTION III: GYNECOLOGIC ONCOLOGY
Antibody–Drug Conjugates for the Treatment of Gynecologic Cancer: A Review of the Current Evidence and Clinical Application
Key points
Introduction
Antibody–drug conjugates for the treatment of epithelial ovarian, fallopian tube, and primary peritoneal cancers
Ongoing trials in epithelial ovarian, fallopian tube, and primary peritoneal cancers
Antibody–drug conjugates for the treatment of cervical cancer
Ongoing trials in cervical cancer
Antibody–drug conjugates for the treatment of endometrial cancer
Summary
Clinics care points
Surgery for Recurrent Ovarian Cancer
Key points
Introduction
Patient selection
Evaluation of clinical benefit
Future directions
Summary
Clinics care points
SECTION IV: PEDIATRIC ONCOLOGY
Big Data in Pediatric Oncology: Hope, Hype, Reality
Key points
Introduction
What is big data?
Advances in big data and medicine
The promise of big data
Big data challenges
Successes in big data
The future of big data in pediatric oncology
Summary
Clinics care points
SECTION V: NEURO-ONCOLOGY
Imipridones and Dopamine Receptor Antagonism in the Therapeutic Management of Gliomas
Key points
Introduction
Dopamine receptors in cancer and gliomas
Imipridone mechanism of action
Imipridone preclinical efficacy and early phase clinical trials
Imipridone later stage clinical trials and future directions
Future directions
Funding
Diagnostic and Theranostic Opportunities in Neuro-Oncology
Key points
Introduction
Challenges in neuro-oncology
Imaging challenges and opportunities
The nuts and bolts of theranostics
Nuclear medicine approaches to theranostics
MRI approaches to theranostics
Summary
Updates on Revised Diagnostic Criteria and Targeted Therapies for Neurofibromatosis
Key points
Introduction
Revised diagnostic criteria for NF1
Revised diagnostic criteria for NF2-SWN and non-NF2-SWN
Systemic therapies for NF1
Systemic therapies for NF2-SWN
Systemic therapies for non-NF2-SWN
Summary
Clinics care points
SECTION VI: HEMATOLOGICAL ONCOLOGY
Management of Relapsed Refractory Large B-Cell Non-Hodgkin Lymphoma: Chimeric Antigen Receptor T-Cell Therapy versus Autologous Stem Cell Transplantation
Key points
Introduction
Autologous hematopoietic stem cell transplant
Chimeric antigen receptor T-cell therapy
Discussion
Summary
Clinics care points
T-cell Acute Lymphoblastic Leukemia: Novel Therapies Worth Watching
Key points
Introduction
Summary
Prognostic Role and Clinical Utility of Measurable Residual Disease in Acute Myeloid Leukemia
Key points
Introduction
Prognostic impact of measurable residual disease in acute myeloid leukemia
Methods for assessing measurable residual disease
Multiparameter flow cytometry-measurable residual disease
Molecular measurable residual disease
Measurable residual disease in various acute myeloid leukemia subsets
Acute promyelocytic leukemia
Core binding factor acute myeloid leukemia
Nucleophosmin-1-mutated acute myeloid leukemia
Measurable residual disease in Wilms’ tumor gene -mutated acute myeloid leukemia
Measurable residual disease as a guide for post-remission therapy
Measurable residual disease utility in lower intensive regimens
Measurable residual disease -eradication strategies
Measurable residual disease in relapsed/refractory acute myeloid leukemia
Future directions
Summary
Clinics care points
SECTION VII: URO-ONCOLOGY
Role of Circulating Tumor DNA for Monitoring of Recurrence and Treatment Response in Urothelial Cancer
Key points
Introduction
Use of ctDNA as a Biomarker for prognosis, progression, and relapse
Summary
Clinics care points
Intensification of Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: Patient Selection and Overview of Doublet and Triplet Therapy Data
Key points
Introduction
General content
Androgen receptor signaling inhibitors
Triplet therapy
Prostate radiotherapy
Patient selection for intensification
When to consider androgen receptor signaling inhibitors in metastatic hormone-sensitive prostate cancer
When to consider docetaxel in metastatic hormone-sensitive prostate cancer
When to consider triplet therapy
When to consider radiotherapy
Discussion
Clinics care points
Adjuvant Therapy for Muscle-Invasive Urothelial Cancer: Current Evidence and Future Directions
Key points
Introduction
Neoadjuvant cisplatin-based chemotherapy
Adjuvant cisplatin-based chemotherapy
Adjuvant immunotherapy
Upper tract urothelial carcinoma
Biomarkers for patient selection for immunotherapy in adjuvant setting
Discussion
SECTION VIII: GASTROINTESTINAL ONCOLOGY
Defining the Role of Neoadjuvant Therapy for Gastroesophageal Cancers
Key points
Introduction
Neoadjuvant treatment in esophageal, gastroesophageal junction, and gastric cancers
Novel biomarker-driven treatments in neoadjuvant treatment of esophageal, gastroesophageal junction, and gastric adenocarcinoma
Summary
Clinics care points
Current and Emerging Therapeutic Options for Human Epidermal Growth Factor Receptor 2-Expressing Gastroesophageal Cancers
Key points
Background
Treatment paradigms by disease state
Treatment strategies under investigation
Mechanisms of resistance to human epidermal growth factor receptor 2-targeted therapy
Circulating tumor DNA tracking of response and resistance
Summary
Clinics care points
Contemporary Systemic Therapy Approaches for Unresectable Hepatocellular Carcinoma
Key points
Introduction
Preferred first-line systemic therapies
Additional first-line therapy considerations
Emerging novel first-line combinations
Preferred second-line systemic therapies (post–first-line sorafenib)
Preferred second-line systemic therapies (post–first-line immunotherapy regimens)
Special patient populations
Summary points
Multidisciplinary Care and Multimodal Treatment Approaches for Unresectable Hepatocellular Carcinoma
Key points
Introduction
Locoregional and multimodality therapy for unresectable, intermediate stage hepatocellular carcinoma
Combined modality therapy for advanced stage hepatocellular carcinoma
Additional management considerations in unresectable hepatocellular carcinoma
Concept integration: case-based unresectable hepatocelluar carcinoma management scenarios
Summary points

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Advances in Oncology, 2024

Purchase options

Institutional subscription on ScienceDirect

Leonidas C. Platanias